title: Thrombolysis and coronary occlusion: effects upon the non-infarct zone.
abstract: Regional wall motion was examined by angiography after 3 weeks in 154 patients taking part in the Thrombolysis in Coronary Occlusion (TICO) Trial. Coronary patency rate was greater after administration of recombinant tissue plasminogen activator, (rt-PA 62/77pts 81%) than after a placebo (P 49/77pts 64% P = 0.02), particularly for the left anterior descending artery compared with the right coronary artery (LAD 27/28 96% vs RCA 28/40 70% P = 0.006). Left ventricular ejection fraction (LVEF) was preserved after rt-PA (rt-PA 59 +/- 14% vs P 53 +/- 15% P = 0.01), predominantly because of more effective non-infarct zone contraction (rt-PA 0.52 +/- 1.16 SD/cord vs P 1.01 +/- 1.07 SD/cord P = 0.008). Infarct zone scores differed little (rt-PA 2.88 +/- 0.95 SD/cord vs P 3.16 +/- 1.11 SD/cord P = 0.09). Left ventricular ejection fraction and non-infarct zone function were best preserved after rt-PA compared with the placebo, particularly in patients with single vessel disease and in patients in whom the infarct-related artery was the left anterior descending vessel.
authors.affiliation: TICO Working Group, Royal North Shore Hospital, St Leonards, Sydney, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Cranswick
authors.forename: G
authors.initials: G
authors.lastname: Carter
authors.forename: N
authors.initials: N
authors.lastname: Wilkes
authors.forename: G
authors.initials: G
authors.lastname: Nelson
mesh_terms: D000328:Adult; D000368:Aged; D003326:Coronary Circulation / Q000502:physiology*; D003331:Coronary Vessels / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000502:physiology*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D013318:Stroke Volume / Q000502:physiology; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome; D014654:Vascular Patency / Q000502:physiology*; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D010959:Tissue Plasminogen Activator